Host: Jennifer Caudle, DO

Guest: Tanguy Seiwert, MD

The immunotherapeutic blockade of checkpoint inhibition that has resulted in stellar improvements in patient outcomes in melanoma and non-small cell lung cancer is now a likelihood for patients with head and neck cancer. Join us as Dr. Tanguy Seiwert discusses the mechanistic basis of checkpoint inhibition and the clinical data demonstrating the efficacy of anti-PD-1 agents in patients with head and neck cancer. Also discussed is the potential value of synergism between anti-checkpoint immunotherapy and current standards of care in head and neck cancer, as well as the growing relevance of biomarkers in identifying patients who will most benefit from immunotherapy.